Resumo
Gliflozins are relatively recent drugs, and have been incorporated into the arsenal of the treatment of diabetics. To these, a favorable cardiovascular effect was attributed to clinical data from diabetic patients treated with similar therapies compared to glyphlozines. The project sought to investigate the performance of these drugs in platelets, since they are emblematic figures in the main pathophysiology of the disease that has the highest cause of death in the world: Coronary artery disease.
Referências
Abdul-Ghani, M.A., Norton, L., and Defronzo, R.A. (2011). Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocrine reviews 32, 515-531.
Davì, G., and Patrono, C. (2007). Platelet activation and atherothrombosis. New England Journal of Medicine 357, 2482- 2494.
Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U.C., and Johansen, O.E. (2015). SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes and vascular disease Research 12, 90-100.
Ruggeri, Z.M. Platelets in atherothrombosis. Nature medicine 8, 1227-1234 (2002)
Davì, G., and Patrono, C. (2007). Platelet activation and atherothrombosis. New England Journal of Medicine 357, 2482- 2494.
Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U.C., and Johansen, O.E. (2015). SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes and vascular disease Research 12, 90-100.
Ruggeri, Z.M. Platelets in atherothrombosis. Nature medicine 8, 1227-1234 (2002)
Todos os trabalhos são de acesso livre, sendo que a detenção dos direitos concedidos aos trabalhos são de propriedade da Revista dos Trabalhos de Iniciação Científica da UNICAMP.
Downloads
Não há dados estatísticos.